The addition of trametinib to dabrafenib improved health-related quality of life and reduced pain in patients with BRAF V600-mutated metastatic melanoma, according to results of a randomized phase 3 study.
MRV Research
Adjuvant ipilimumab improves survival after high-risk lymph node and melanoma resection
Results of an EORTC trial show that adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but this treatment is also associated with a high rate of immune-related adverse events.
Researchers Discover a Promising New Drug Target for Melanoma Treatment
A team of researchers from The University of North Carolina at Chapel Hill have recently reported the discovery of a new drug target for melanoma treatment. The study was published in the journal Clinical Cancer Research and is entitled “IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.”
Robert H. Pierce, MD, Chief Scientific Officer of OncoSec Medical, Invited to Present at 11th Annual PEGS Conference in Boston
Preliminary Results Suggest ImmunoPulse™ IL-12 May Generate Increased TILs and CD8+ T-Cell Infiltration in Merkel Cell Carcinoma and Melanoma Patients